Invivyd Inc. (IVVD) NASDAQ
$2.48 (0.22) (-8.15%)
Market Cap: $321.90M
As of 04/17/24 04:00 PM EDT. Market closed.
Invivyd Inc. (IVVD)
NASDAQ
$2.48
(0.22) (-8.15%)
Market Cap: $321.90M
As of 04/17/24 04:00 PM EDT. Market closed.
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody ... read more
adagio is developing best-in-class antibodies that can broadly neutralize sars-cov-2, sars-cov-1 and additional potentially emergent coronaviruses. we believe our antibodies will match or exceed the potency and coverage of conventional sars-cov-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. our candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. our portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. our lead program is expected to enter the clinic by the end of 2020. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Adimab, LLC | 10% Owner | Jan 19, 2024 | Sale | $3.95 | 5,000,000 | 19,750,000 | 21,687,906 | Jan 22, 2024, 04:18 PM |
| Hering David | Chief Executive Officer | Sep 01, 2022 | Buy | $4.52 | 8,000 | 36,160 | 8,000 | Sep 01, 2022, 04:28 PM |
| Elia Marc | Director | Aug 19, 2022 | Buy | $4.62 | 584,451 | 2,700,164 | 9,248,250 | Aug 19, 2022, 04:57 PM |
| Elia Marc | Director | Aug 18, 2022 | Buy | $4.31 | 1,265,549 | 5,454,516 | 8,663,799 | Aug 19, 2022, 04:57 PM |
| Elia Marc | Director | Aug 17, 2022 | Buy | $4.04 | 1,000,000 | 4,040,000 | 7,398,250 | Aug 19, 2022, 04:57 PM |
| Royan Ajay | Director | Aug 10, 2021 | Buy | $17.00 | 1,997,000 | 33,949,000 | 11,241,580 | Aug 12, 2021, 09:27 PM |
| MITHRIL II LP | 10% Owner | Aug 10, 2021 | Buy | $17.00 | 1,997,000 | 33,949,000 | 11,241,580 | Aug 12, 2021, 09:25 PM |
| MCGUIRE TERRANCE | Director | Aug 10, 2021 | Buy | $17.00 | 500,000 | 8,500,000 | 4,800,460 | Aug 12, 2021, 09:24 PM |
| Redmile Group, LLC | 10% Owner | Aug 10, 2021 | Buy | $17.00 | 1,470,000 | 24,990,000 | 3,390,960 | Aug 12, 2021, 09:01 PM |
| Owner | Relationship | Date | Value($) |
| Adimab, LLC | 10% Owner | 01/19/2024 | 19,750,000 |
| Hering David | Chief Executive Officer | 09/01/2022 | 36,160 |
| Elia Marc | Director | 08/19/2022 | 2,700,164 |
| Elia Marc | Director | 08/18/2022 | 5,454,516 |
| Elia Marc | Director | 08/17/2022 | 4,040,000 |
| Royan Ajay | Director | 08/10/2021 | 33,949,000 |
| MITHRIL II LP | 10% Owner | 08/10/2021 | 33,949,000 |
| MCGUIRE TERRANCE | Director | 08/10/2021 | 8,500,000 |
| Redmile Group, LLC | 10% Owner | 08/10/2021 | 24,990,000 |
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| MAVERICK CAPITAL LTD | 9,343,949 | 0.74% | 77.29% | Growth At A Reasonable Price, Growth |
| ORBIMED ADVISORS LLC | 4,127,565 | 0.32% | -21.68% | Other |
| BLACKROCK INC. | 899,980 | 0.00009% | -20.45% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 581,090 | 0.00024% | 6.88% | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 86,787 | 0.00064% | New | Event Driven |
| RENAISSANCE TECHNOLOGIES LLC | 27,200 | 0.00017% | -44.25% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View